Key Events This Week
2 Mar: Stock hits 52-week low at Rs.142.95 amid sharp gap down
4 Mar: Slight recovery with modest gains despite Sensex decline
5 Mar: Continued marginal gains as Sensex rebounds
6 Mar: Week closes lower at Rs.152.05, down 0.91% on the day
2 March: Sharp Gap Down and New 52-Week Low
Piramal Pharma opened the week with a significant gap down of 8.45%, opening at Rs.142.95, which marked a fresh 52-week low. This sharp decline was triggered by a downgrade to a ‘Strong Sell’ rating by MarketsMOJO on 18 February 2026, reflecting deteriorating fundamentals and heightened investor caution. The stock closed the day at Rs.152.95, down 2.05%, underperforming the Sensex which fell 1.41% to 35,812.02.
The intraday low and opening price coincided at Rs.142.95, underscoring the intensity of selling pressure. This decline extended a two-day losing streak, with the stock falling 6.75% over that period. Technical indicators showed the stock trading below all key moving averages, signalling sustained bearish momentum. The company’s elevated Debt to EBITDA ratio of 3.83 times and consecutive quarterly losses further weighed on sentiment.
4 March: Modest Recovery Amid Market Weakness
After the steep drop, Piramal Pharma posted a modest gain of 0.10% to close at Rs.153.10 on 4 March, despite the Sensex declining 1.92% to 35,125.64. The volume surged to over 1.36 million shares, indicating increased trading interest. This slight rebound suggested some short-term buying support, although the stock remained below critical moving averages. The broader market weakness and sector challenges continued to cap upside potential.
Just announced: This Small Cap from Tyres & Allied with precise target price is our pick for the week. Get the pre-market insights that informed this selection!
- - Just announced pick
- - Pre-market insights shared
- - Tyres & Allied weekly focus
5 March: Continued Gains as Sensex Rebounds
The stock extended its modest recovery on 5 March, rising 0.23% to Rs.153.45, while the Sensex rebounded 1.29% to 35,579.03. However, trading volume declined sharply to 88,303 shares, indicating cautious participation. Despite the gains, Piramal Pharma remained under pressure from its weak earnings profile and technical bearishness. The company’s negative EPS of Rs.-1.03 and losses in recent quarters continued to dampen investor enthusiasm.
6 March: Week Ends Lower Amid Renewed Selling
On the final trading day of the week, Piramal Pharma closed at Rs.152.05, down 0.91%, as the Sensex fell 0.98% to 35,232.05. Volume was subdued at 45,669 shares. The stock’s decline on the day capped a week marked by volatility and a general downtrend. The persistent gap down and technical weakness, combined with the company’s ‘Strong Sell’ Mojo Grade of 26.0, reinforced the cautious outlook.
Considering Piramal Pharma Ltd? Wait! SwitchER has found potentially better options in and beyond. Compare this small-cap with top-rated alternatives now!
- - Better options discovered
- - + beyond scope
- - Top-rated alternatives ready
Weekly Price Performance: Piramal Pharma vs Sensex
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-03-02 | Rs.152.95 | -2.05% | 35,812.02 | -1.41% |
| 2026-03-04 | Rs.153.10 | +0.10% | 35,125.64 | -1.92% |
| 2026-03-05 | Rs.153.45 | +0.23% | 35,579.03 | +1.29% |
| 2026-03-06 | Rs.152.05 | -0.91% | 35,232.05 | -0.98% |
Key Takeaways
Persistent Downtrend and Technical Weakness: The stock’s trading below all major moving averages and a ‘Strong Sell’ Mojo Grade of 26.0 highlight ongoing bearish momentum and cautious market sentiment.
Significant Gap Down and 52-Week Low: The week began with an 8.45% gap down to Rs.142.95, marking the lowest price in a year and signalling intensified selling pressure.
Financial Challenges: Elevated leverage with a Debt to EBITDA ratio of 3.83 times and three consecutive quarters of losses, including a recent EPS of Rs.-1.03, continue to weigh on the stock’s fundamentals.
Relative Outperformance vs Sensex: Despite the negative trend, Piramal Pharma’s weekly decline of 2.63% was less severe than the Sensex’s 3.00% fall, indicating some resilience amid broader market weakness.
Conclusion
Piramal Pharma Ltd’s share price experienced a challenging week marked by a sharp gap down, a new 52-week low, and sustained technical weakness. The downgrade to a ‘Strong Sell’ rating and ongoing financial difficulties have contributed to a cautious outlook. While the stock marginally outperformed the broader Sensex decline, the prevailing negative momentum and fundamental concerns suggest continued volatility ahead. Investors should closely monitor the company’s earnings trajectory and leverage metrics as key indicators of potential recovery or further pressure.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
